Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Adknoma Health Research | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
The SOGUG-TIVOREAL study is a retrospective observational study with medications.
This study is based on the retrospective collection of data from patients who have been treated with Tivozanib as first-line therapy between 03/01/2019 and 08/31/2024 for metastatic renal cell carcinoma (mRCC).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Progression-free survival (PFS) | To evaluate the progression-free survival (PFS) in patients with metastatic clear cell renal cell carcinoma (mRCC) from the favorable risk group according to IMDC, treated with Tivozanib monotherapy as first-line therapy. The probability of progression-free survival will be described using the Kaplan-Meier method, along with the 95% confidence intervals of the point estimates, as well as the median time of survival from the start of treatment with Tivozanib until tumor progression or death from any cause, whichever occurs first. RECIST 1.1 | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival (OS) in favorable risk group | To evaluate the overall survival (OS) of patients with metastatic clear cell renal cell carcinoma (mRCC) from the favorable risk group according to IMDC, treated with Tivozanib monotherapy as first-line therapy. The probability of overall survival will be described using the Kaplan-Meier method, along with the 95% confidence intervals of the point estimates, as well as the median survival time from the start of treatment with Tivozanib until death from any cause. RECIST 1.1 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The population of this study consists of patients diagnosed with metastatic renal cell carcinoma (mRCC) who initiated first-line treatment with Tivozanib between March 1, 2019, and August 31, 2024.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Reina Sofia | Córdoba | Andalusia | Spain | |||
| Hospital Virgen de la Victoria |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Day 1 |
| Objective response rate (ORR) in favorable risk group | To evaluate the objective response rate (ORR) in patients with metastatic clear cell renal cell carcinoma (mRCC) from the favorable risk group according to IMDC, treated with Tivozanib monotherapy as first-line therapy. ORR is defined as the percentage of patients with tumor size reduction (PR) and/or disappearance (CR) after treatment. RECIST 1.1 | Day 1 |
| Percentage of patients with PR and CR in favorable risk group | To evaluate the percentage of patients with partial response (PR) and complete response (CR) among those with metastatic clear cell renal cell carcinoma (mRCC) from the favorable risk group according to IMDC, treated with Tivozanib monotherapy as first-line therapy. RECIST 1.1 | Day 1 |
| Progression-free survival (PFS) - Intermediate and poor risk group | To evaluate the progression-free survival (PFS) in patients with metastatic clear cell renal cell carcinoma (mRCC) from the intermediate and poor risk groups according to IMDC, treated with Tivozanib monotherapy as first-line therapy. The probability of progression-free survival will be described using the Kaplan-Meier method, along with the 95% confidence intervals of the point estimates, as well as the median time of survival from the start of treatment with Tivozanib until tumor progression or death from any cause, whichever occurs first. RECIST 1.1 | Day 1 |
| Overall survival (OS) - Intermediate and poor risk group | To evaluate the overall survival (OS) in patients with metastatic clear cell renal cell carcinoma (mRCC) from the intermediate and poor risk groups according to IMDC, treated with Tivozanib monotherapy as first-line therapy. The probability of overall survival will be described using the Kaplan-Meier method, along with the 95% confidence intervals of the point estimates, as well as the median survival time from the start of treatment with Tivozanib until death from any cause. RECIST 1.1 | Day 1 |
| Objective response rate (ORR) in poor and intermediate risk group | To evaluate the objective response rate (ORR) in patients with metastatic clear cell renal cell carcinoma (mRCC) from the intermediate and poor risk groups according to IMDC, treated with Tivozanib monotherapy as first-line therapy. ORR is defined as the percentage of patients with tumor size reduction (PR) and/or disappearance (CR) after treatment. RECIST 1.1 | Day 1 |
| Percentage of patients with PR and CR in intermediate and poor risk group | To evaluate the percentage of patients with partial response (PR) and complete response (CR) among those with metastatic clear cell renal cell carcinoma (mRCC) from the intermediate and poor risk groups according to IMDC, treated with Tivozanib monotherapy as first-line therapy. RECIST 1.1 | Day 1 |
| Toxicity profile of Tivozanib | To evaluate the toxicity profile of Tivozanib in the entire study population during the treatment period with Tivozanib, through the evaluation of tivozanib-related toxicities reported in the patients' medical history | Day 1 |
| Málaga |
| Andalusia |
| Spain |
| Hospital Virgen del Rocio | Seville | Andalusia | Spain |
| Hospital de Burgos | Burgos | Castille and León | Spain |
| Hospital de Leon | León | Castille and León | Spain |
| Hospital Vall de Hebron | Barcelona | Catalonia | Spain |
| Institut Català d'Oncologia (ICO) de L'Hospitalet de Llobregat | L'Hospitalet de Llobregat | Catalonia | Spain |
| Hospital Parc Tauli | Sabadell | Catalonia | Spain |
| Hospital Lucus Augusti | Lugo | Galicia | Spain |
| Hospital Severo Ochoa | Leganés | Madrid | Spain |
| Fundacion Jimenez Diaz | Madrid | Madrid | Spain |
| Hospital Gregorio Marañon | Madrid | Madrid | Spain |
| Hospital Puerta de Hierro | Majadahonda | Madrid | Spain |
| Instituto Valenciano de Oncologia (IVO) | Valencia | Valencia | Spain |